Skip to main content

Table 2 Base case model results after price negotiation

From: Cost-effectiveness analysis of fruquintinib for metastatic colorectal cancer third-line treatment in China

Strategy

Fruquintinib

Placebo

Cost, USD

20,750.9

12,042.2

Effect, QALY

0.6404

0.4776

IC, USD

8708.7

–

IE, QALY

0.16275

–

ICER, USD per QALY

53,508.7

–

  1. Abbreviations: IC incremental cost, IE incremental effectiveness, ICER incremental cost-effectiveness ratio, QALY quality-adjusted life-years